Biopharma | November 28, 2025
Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GV20 received an upfront payment and is eligible for additional milestone payments
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The initiative aims to connect startups and tech companies with its business units,
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Subscribe To Our Newsletter & Stay Updated
